Public drug quality ratings would benefit patients and consumers, US Food and Drug Administration officials and health care providers agreed at a recent Duke Margolis Center for Health Policy workshop in Washington, DC, that was marked by sharp differences between the agency and providers over the current state of quality.
Agency officials focused on how they are assuring the public of acceptable brand and generic drug quality, while providers raised concerns about ways the agency may be failing to protect...
